{
    "nct_id": "NCT03962647",
    "official_title": "A Pilot and Feasibility Neoadjuvant Study of a 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer",
    "inclusion_criteria": "* All participants must provide written informed consent.\n* Patients must have histologically confirmed primary invasive mammary carcinoma\n\n  * The tumor must be estrogen receptor positive\n  * The tumor must be HER2 negative (negative IHC or FISH)\n  * The primary tumor size must be at least 2 mm in size.\n* Patients must be post-menopausal defined by any of the following:\n\n  * Subjects at least 55 years of age.\n  * Subjects younger than 55 years of age and amenorrheic for at least 12 months or serum follicle-stimulating hormone (FSH) levels and estradiol levels in the post-menopausal range by local lab criteria\n  * Subjects with history of bilateral oophorectomy or prior radiation castration with amenorrhea for at least 6 months.\n* Patients must have clinical stage I, II, or III invasive mammary carcinoma planning to undergo surgical treatment with either segmental resection or total mastectomy.\n* Patients must have BMI >= 30.\n* A core biopsy from the time of diagnosis must be available.\n* Mammogram or ultrasound required prior to screening\n* Patients must have adequate organ function based on the following laboratory parameters:\n\n  * Serum creatinine <= 1.5x ULN\n  * SGOT, SGPT <= 4x ULN (unless known steatohepatitis)\n  * Serum albumin >= 2.0 g/dL\n  * Total serum bilirubin <= 1.5x ULN (or <= 3x ULN if known Gilbert's syndrome)\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "Patients with locally advanced disease who are candidates for other preoperative (chemo)therapy at the time of initial evaluation. This includes patients with inflammatory breast cancer.\n\n* Evidence of distant metastatic disease (stage IV).\n* Serious medical illness that in the judgment of the treating physician places the patient at high risk of operative mortality.\n* Serious medical illness that in the judgment of the treating physician would preclude the use of a ketogenic diet.\n* Severe uncontrolled malabsorption condition or disease (e.g. grade II/III diarrhea, severe malnutrition, short gut syndrome).\n* Diabetes mellitus requiring insulin therapy.\n* Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.\n* Participation in any other neoadjuvant therapeutic clinical trial.\n* Concurrent anti-cancer therapy other than endocrine therapy (e.g. chemotherapy, radiotherapy, immunotherapy, or any other biologic therapy).\n* Concurrent treatment with an investigational agent.\n* Use of an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first day of dietary intervention.",
    "miscellaneous_criteria": ""
}